Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Sees Significant Growth in Short Interest

Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) saw a large growth in short interest during the month of March. As of March 15th, there was short interest totalling 23,900 shares, a growth of 119.3% from the February 29th total of 10,900 shares. Based on an average trading volume of 23,500 shares, the short-interest ratio is presently 1.0 days. Approximately 2.8% of the company’s shares are sold short.

Hedge Funds Weigh In On Virpax Pharmaceuticals

Several institutional investors have recently modified their holdings of the stock. Citigroup Inc. bought a new position in Virpax Pharmaceuticals during the 1st quarter worth approximately $27,000. Renaissance Technologies LLC acquired a new stake in Virpax Pharmaceuticals in the first quarter worth $348,000. Finally, Vanguard Group Inc. boosted its position in shares of Virpax Pharmaceuticals by 4.5% during the first quarter. Vanguard Group Inc. now owns 341,977 shares of the company’s stock worth $759,000 after purchasing an additional 14,672 shares in the last quarter. 32.23% of the stock is currently owned by institutional investors and hedge funds.

Virpax Pharmaceuticals Trading Up 13.0 %

NASDAQ VRPX opened at $4.26 on Friday. Virpax Pharmaceuticals has a 12 month low of $2.40 and a 12 month high of $11.77. The stock has a 50-day simple moving average of $3.64 and a 200 day simple moving average of $5.03. The company has a market capitalization of $4.99 million, a PE ratio of -0.36 and a beta of 1.30.

About Virpax Pharmaceuticals

Virpax Pharmaceuticals, Inc, a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.